Gina Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gina Zhu has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Byers
Amplified Sciences, Inc., West Lafayette, IN 47906, USA
1 shared publication - Charles S. Craik
University of California, San Francisco
1 shared publication - Daniel A. Sheik
Amplified Sciences, Inc., West Lafayette, IN 47906, USA
1 shared publication - Francesco Caiazza
UCD School of Medicine and Medical Science, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland
1 shared publication - Kimberly S. Kirkwood
Department of Surgery, Division of Surgical Oncology, University of California, San Francisco, CA 94143, USA
1 shared publication - Ummadisetti Chinna Rajesh
Amplified Sciences, Inc., West Lafayette, IN 47906, USA
1 shared publication
Latest Publications
- Open Access
- 28 May 2022
- Published by MDPI AG in Diagnostics
- Vol. 12 (6) , 1343
Translation of a Protease Turnover Assay for Clinical Discrimination of Mucinous Pancreatic Cysts
The classification of pancreatic cyst fluids can provide a basis for the early detection of pancreatic cancer while eliminating unnecessary procedures. A candidate biomarker, gastricsin (pepsin C), was found to be present in potentially malignant mucinous pancreatic cyst fluids. A gastricsin activity assay using a magnetic bead-based platform has been developed using immobilized peptide substrates selective for gastricsin bearing a dimeric rhodamine dye. The unique dye structure allows quantitation of enzyme-cleaved product by both fluorescence and surface enhanced Raman spectroscopy (SERS). The performance of this assay was compared with ELISA assays of pepsinogen C and the standard of care, carcinoembryonic antigen (CEA), in the same clinical sample cohort. A retrospective cohort of mucinous (n = 40) and non-mucinous (n = 29) classes of pancreatic cyst fluid samples were analyzed using the new protease activity assay. For both assay detection modes, successful differentiation of mucinous and non-mucinous cyst fluid was achieved using 1 µL clinical samples. The activity-based assays in combination with CEA exhibit optimal sensitivity and specificity of 87% and 93%, respectively. The use of this gastricsin activity assay requires a minimal volume of clinical specimen, offers a rapid assay time, and shows improvements in the differentiation of mucinous and non-mucinous cysts using an accurate standardized readout of product formation, all without interfering with the clinical standard of care.
- 28 May 2022
- Published by MDPI AG in Diagnostics
- Vol. 12 (6) , 1343
Open AccessTranslation of a Protease Turnover Assay for Clinical Discrimination of Mucinous Pancreatic Cysts
The classification of pancreatic cyst fluids can provide a basis for the early detection of pancreatic cancer while eliminating unnecessary procedures. A candidate biomarker, gastricsin (pepsin C), was found to be present in potentially malignant mucinous pancreatic cyst fluids. A gastricsin activity assay using a magnetic bead-based platform has been developed using immobilized peptide substrates selective for gastricsin bearing a dimeric rhodamine dye. The unique dye structure allows quantitation of enzyme-cleaved product by both fluorescence and surface enhanced Raman spectroscopy (SERS). The performance of this assay was compared with ELISA assays of pepsinogen C and the standard of care, carcinoembryonic antigen (CEA), in the same clinical sample cohort. A retrospective cohort of mucinous (n = 40) and non-mucinous (n = 29) classes of pancreatic cyst fluid samples were analyzed using the new protease activity assay. For both assay detection modes, successful differentiation of mucinous and non-mucinous cyst fluid was achieved using 1 µL clinical samples. The activity-based assays in combination with CEA exhibit optimal sensitivity and specificity of 87% and 93%, respectively. The use of this gastricsin activity assay requires a minimal volume of clinical specimen, offers a rapid assay time, and shows improvements in the differentiation of mucinous and non-mucinous cysts using an accurate standardized readout of product formation, all without interfering with the clinical standard of care.